Literature DB >> 30227171

ARL3 subcellular localization and its suspected role in autophagy.

Guanghong Luo1, Yangyang Sun1, Ruili Feng1, Qinping Zhao1, Tieqiao Wen2.   

Abstract

ADP-ribosylation factor-like3 (ARL3) is a member of the ADP-ribosylation factor family of GTP-binding proteins that plays important role in regulating Ciliary trafficking. It ubiquitously expressed in normal tissues and tumor cell lines. However, the location and function of ARL3 in organelles are rarely known. In this study, we explored ARL3 subcellular localization in an all-round way in HEK293T, Neuro-2A and U251 cells by density gradient centrifugation and immunofluorescence. The results showed that ARL3 is expressed in most of organelles, and an iodixonal step gradient was further confirmed that ARL3 is mainly localized to the mitochondria, endosomes, lysosomes, and proteasome. By molecular functional analysis, we observed that ARL3 promotes the aggregation of GFP-LC3, up-regulation of LC3-II/LC3-I and down-regulation of SQSMT1/BECN1, and knocking down of ARL3 inbibits autophagy, which suggested that ARL3 is necessary for autophagy. this study presents a comprehensive evaluation of the subcellular localization for ARL3 and provides important on understanding the functions of ARL3.
Copyright © 2018 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights reserved.

Entities:  

Keywords:  ARL3; Autophagy; Endosome; Lysosome; Mitochondria

Mesh:

Substances:

Year:  2018        PMID: 30227171     DOI: 10.1016/j.biochi.2018.09.007

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  2 in total

1.  ARL3 is downregulated and acts as a prognostic biomarker in glioma.

Authors:  Yulin Wang; Weijiang Zhao; Xin Liu; Gefei Guan; Minghua Zhuang
Journal:  J Transl Med       Date:  2019-06-24       Impact factor: 5.531

2.  Transcriptomes of peripheral blood mononuclear cells from juvenile dermatomyositis patients show elevated inflammation even when clinically inactive.

Authors:  Elisha D O Roberson; Rosana A Mesa; Gabrielle A Morgan; Li Cao; Wilfredo Marin; Lauren M Pachman
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.